Hybryte™ phase 3 flash study for the treatment of cutaneous t-cell lymphoma published in jama dermatology

Published findings demonstrate that hybryte™ treatment statistically significantly reduced ctcl lesion size hybryte™ has potential to address a critical gap in treatment of early-stage ctcl princeton, n.j. , july 20, 2022 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the results of its successful phase 3 flash (fluorescent light activated synthetic hypericin) study evaluating hybryte™ (synthetic hypericin) for the treatment of cutaneous t-cell lymphoma (ctcl) has been published in the journal of the american medical association (jama) dermatology.
SNGX Ratings Summary
SNGX Quant Ranking